Anifrolumab-fnia, an IFNAR1-blocking monoclonal antibody, is now authorized for weekly subcutaneous self-administration in ...

AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector ...

AstraZeneca's Saphnelo (anifrolumab) has been approved in the US for self-administration as a once-weekly autoinjector, the Saphnelo Pen, for the ...

TORONTO — Health Canada has approved the first needle-free epinephrine treatment for severe allergic reactions: a nasal spray ...

UCB, a global biopharmaceutical company, today announced data from two clinical studies assessing ZLP-AI in adult patients who are anti-AChR antibody positivegMG as well as in healthy volunteers. The ...

A newly developed autoinjector is described as a “major leap forward in how autoinjectors are developed, customized, and scaled,” according to contract development and manufacturing organization (CDMO ...

The Furoscix on-body infusor. [Image courtesy of MannKind] MannKind (Nasdaq:MNKD) announced today that the FDA approved its Furoscix (furosemide) on-body infusor for pediatric patients. The company ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The development process for the ...

Please provide your email address to receive an email when new articles are posted on . Feasibility and acceptability scores for the autoinjector were highest among health care professionals. All ...

A Prescription Drug User Fee Act target date of July 26, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application ...

Sempresto, Inc., a medical device company pioneering smartphone-integrated rescue drug delivery, today announced the acquisition of all patents and related physical and digital assets from inventor ...